US2018170941A1PendingUtilityA1
Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
Est. expiryDec 19, 2036(~10.4 yrs left)· nominal 20-yr term from priority
A61P 25/00C07D 487/14A61K 31/5517A61K 31/13A61P 35/00A61K 45/06A61P 25/28
47
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of those benzodiazepine derivatives and methods of using those derivatives or compositions in treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of a α5-containing GABA A receptor agonist (e.g., a α5-containing GABA A receptor positive allosteric modulator) as described herein in treating cognitive impairment associated with central nervous system (CNS) disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI (aMCI), Age-Associated Memory Impairment (AAMI), Age Related Cognitive Decline (ARCD), dementia, Alzheimer's Disease(AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis (ALS), cancer-therapy-related cognitive impairment, mental retardation, Parkinson's disease (PD), autism spectrum disorders, fragile X disorder, Rett syndrome, compulsive behavior, and substance addiction. It also relates to the use of a α5-containing GABA A receptor agonist (e.g., a α5-containing GABA A receptor positive allosteric modulator) as described herein in treating brain cancers (including brain tumors, e.g., medulloblastomas), and cognitive impairment associated therewith.
Claims
exact text as granted — not AI-modified1 . A compound of formula I:
or a pharmaceutically acceptable salt, hydrate, solvate, polymorph, isomer, or combination thereof, wherein:
U and the two carbon atoms designated by α and β together form a 5- or 6-membered aromatic ring having 0-2 nitrogen atoms;
A is C, CR 6 , or N;
B and F are each independently selected from C, CR 6 , and N, wherein B and F cannot both be N;
D is N, NR 7 , O, CR 6 or C(R 6 ) 2 ;
E is N, NR 7 , CR 6 or C(R 6 ) 2 ;
W is N, NR 7 , CR 6 or C(R 6 ) 2 ;
X is N, NR 7 , O, CR 6 or C(R 6 ) 2 ;
Y and Z are each independently selected from C, CR 6 , and N, wherein Y and Z cannot both be N;
V is C or CR 6 ,
or when Z is C or CR 6 , V is C, CR 6 , or N;
wherein when the ring formed by X, Y, Z, V and W is then R 2 is —OR 8 , —SR 8 , —(CH 2 ) n OR 8 , —(CH 2 ) n O(CH 2 ) n R 8 , —(CH 2 ) p R 8 and —(CH 2 ) n N(R″)R 10 ; and wherein R 2 is independently substituted with 0-5 R′;
m and n are independently integers selected from 0-4;
p is an integer selected from 2-4;
each occurrence of the bond “ ” is either a single bond or a double bond;
each occurrence of R 1 R 2 , R 4 , and R 5 are each independently selected from:
halogen, —R, —OR, —NO 2 , —NCS, —CN, —CF 3 , —OCF 3 , —SiR 3 , —N(R) 2 , —SR, —SOR, —SO 2 R, —SO 2 N(R) 2 , —SO 3 R, —(CR 2 ) 1-3 R, —(CR 2 ) 1-3 —OR, —(CR 2 ) 0-3 —C(O)NR(CR 2 ) 0-3 R, —(CR 2 ) 0-3 —C(O)NR(CR 2 ) 0-3 OR, —C(O)R, —C(O)C(O)R, —C(O)CH 2 C(O)R, —C(S)R, —C(S)OR, —C(O)OR, —(O)C(O)OR, —(O)C(O)N(R) 2 , —OC(O)R, —C(O)N(R) 2 , —OC(O)N(R) 2 , —C(S)N(R) 2 , —(CR 2 ) 0-3 NHC(O)R, —N(R)N(R)COR, —N(R)N(R)C(O)OR, —N(R)N(R)CON(R) 2 , —N(R)SO 2 R, —N(R)SO 2 N(R) 2 , —N(R)C(O)OR, —N(R)C(O)R, —N(R)C(S)R, —N(R)C(O)N(R) 2 , —N(R)C(S)N(R) 2 , —N(COR)COR, —N(OR)R, —C(═NH)N(R) 2 , —C(O)N(OR)R, —C(═NOR)R, —OP(O)(OR) 2 , —P(O)(R) 2 , —P(O)(OR) 2 , and —P(O)(H)(OR);
R 3 is absent or is selected from:
halogen, —R, —OR, —NO 2 , —NCS, —CN, —CF 3 , —OCF 3 , —SiR 3 , —N(R) 2 , —SR, —SOR, —SO 2 R, —SO 2 N(R) 2 , —SO 3 R, —(CR 2 ) 1-3 R, —(CR 2 ) 1-3 —OR, —(CR 2 ) 0-3 —C(O)NR(CR 2 ) 0-3 R, —(CR 2 ) 0-3 —C(O)NR(CR 2 ) 0-3 OR, —C(O)R, —C(O)C(O)R, —C(O)CH 2 C(O)R, —C(S)R, —C(S)OR, —C(O)OR, —(O)C(O)OR, —(O)C(O)N(R) 2 , —OC(O)R, —C(O)N(R) 2 , —OC(O)N(R) 2 , —C(S)N(R) 2 , —(CR 2 ) 0-3 NHC(O)R, —N(R)N(R)COR, —N(R)N(R)C(O)OR, —N(R)N(R)CON(R) 2 , —N(R)SO 2 R, —N(R)SO 2 N(R) 2 , —N(R)C(O)OR, —N(R)C(O)R, —N(R)C(S)R, —N(R)C(O)N(R) 2 , —N(R)C(S)N(R) 2 , —N(COR)COR, —N(OR)R, —C(═NH)N(R) 2 , —C(O)N(OR)R, —C(═NOR)R, —OP(O)(OR) 2 , —P(O)(R) 2 , —P(O)(OR) 2 , and —P(O)(H)(OR);
each R 6 is independently —H or —(C1-C6)alkyl;
each R 7 is independently —H or —(C1-C6)alkyl;
each R 8 is independently —(C1-C6)alkyl, —(C3-C10)-cycloalkyl, (C6-C10)-aryl, or 5- to 10-membered heteroaryl, wherein each occurrence of R 8 is independently substituted with 0-5 R′;
each R 10 is independently —(C3-C10)-cycloalkyl, 3- to 10-membered heterocyclyl-, (C6-C10)-aryl, or 5- to 10-membered heteroaryl, wherein each occurrence of R 10 is independently substituted with 0-5 R′;
each R is independently selected from:
H—,
(C1-C12)-aliphatic-,
(C3-C10)-cycloalkyl-,
(C3-C10)-cycloalkenyl-,
[(C3-C10)-cycloalkyl]-(C1-C12)-aliphatic-,
[(C3-C10)-cycloalkenyl]-(C1-C12)-aliphatic-,
[(C3-C10)-cycloalkyl]-O—(C1-C12)-aliphatic-,
[(C3-C10)-cycloalkenyl]-O—(C1-C12)-aliphatic-,
(C6-C10)-aryl-,
(C6-C10)-aryl-(C1-C12)aliphatic-,
(C6-C10)-aryl-O—(C1-C12)aliphatic-,
(C6-C10)-aryl-N(R″)—(C1-C12)aliphatic-,
3- to 10-membered heterocyclyl-,
(3- to 10-membered heterocyclyl)-(C1-C12)aliphatic-,
(3- to 10-membered heterocyclyl)-O—(C1-C12)aliphatic-,
(3- to 10-membered heterocyclyl)-N(R″)—(C1-C12)aliphatic-,
5- to 10-membered heteroaryl-,
(5- to 10-membered heteroaryl)-(C1-C12)-aliphatic-,
(5- to 10-membered heteroaryl)-O—(C1-C12)-aliphatic-; and
(5- to 10-membered heteroaryl)-N(R″)—(C1-C12)-aliphatic-;
wherein said heterocyclyl has 1-4 heteroatoms independently selected from N, NH, O, S, SO, and SO 2 , and said heteroaryl has 1-4 heteroatoms independently selected from N, NH, O, and S;
wherein each occurrence of R is independently substituted with 0-5 R′;
or when two R groups bound to the same atom, the two R groups may be taken together with the atom to which they are bound to form a 3- to 10-membered aromatic or non-aromatic ring having 0-4 heteroatoms independently selected from N, NH, O, S, SO, and SO 2 , wherein said ring is optionally substituted with 0-5 R′, and wherein said ring is optionally fused to a (C6-C10)aryl, 5- to 10-membered heteroaryl, (C3-C10)cycloalkyl, or a 3- to 10-membered heterocyclyl;
wherein each occurrence of R′ is independently selected from halogen, —R″, —OR″, oxo, —CH 2 OR″, —CH 2 NR″ 2 , —C(O)N(R″) 2 , —C(O)OR″, —NO 2 , —NCS, —CN, —CF 3 , —OCF 3 and —N(R″) 2 ;
wherein each occurrence of R″ is independently selected from H, —(C1-C6)-alkyl, —(C1-C6)-aliphatic, (C3-C6)-cycloalkyl, 3- to 6-membered heterocyclyl, 5- to 10-membered heteroaryl-, (C6-C10)-aryl-, (5- to 10-membered heteroaryl)-(C1-C6)-alkyl-, (C6-C10)-aryl-(C1-C6)-alkyl-, (5- to 10-membered heteroaryl)-O—(C1-C6)-alkyl-, and (C6-C10)-aryl-O—(C1-C6)-alkyl-, wherein each occurrence of R″ is independently substituted with 0-3 substituents selected from: halogen, —R o , —OR o , oxo, —CH 2 OR o , —CH 2 N(R o ) 2 , —C(O)N(R o ) 2 , —C(O)OR o , —NO 2 , —NCS, —CN, —CF 3 , —OCF 3 and —N(R o ) 2 , wherein each occurrence of R o is independently selected from: —(C1-C6)-aliphatic, (C3-C6)-cycloalkyl, 3- to 6-membered heterocyclyl, 5- to 10-membered heteroaryl-, and (C6-C10)-aryl-.
2 . A compound of formula II:
m is 0-3;
each R 1 is independently selected from: —Cl, —F, —OMe, and —C ≡CH;
R 2 is halogen, —(CR 2 ) 1-3 OR, or —(CR 2 ) 1-3 —O(CR 2 ) 1-3 —R, wherein each occurrence of R is independently selected from —H, —(C1-C6)alkyl, (C6-C10)-aryl-, or 5- to 10-membered heteroaryl- and (C6-C10)-aryl-(C1-C12)aliphatic-, and wherein each occurrence of R is independently substituted with 0-5 R′;
R 3 is selected from: CN, —C≡CH, —C≡C—(C1-C6)alkyl, —C≡C-phenyl, —COOMe, —COOEt, —(C1-C6)alkyl,
wherein R 3 is substituted with 0-5 R′;
each occurrence of R 4 and R 5 is independently —H or —(C1-C6)alkyl;
each R 6 is independently —H or —(C1-C6)alkyl;
wherein each occurrence of R′ is independently selected from halogen, —R″, —OR″, oxo, —CH 2 OR″, —CH 2 NR″ 2 , —C(O)N(R″) 2 , —C(O)OR″, —NO 2 , —NCS, —CN, —CF 3 , —OCF 3 and —NR 2 ;
wherein each occurrence of R″ is independently selected from H, —(C1-C6)-alkyl, —(C1-C6)-aliphatic, (C3-C6)-cycloalkyl, 3- to 6-membered heterocyclyl, 5- to 10-membered heteroaryl-, (C6-C10)-aryl-, (5- to 10-membered heteroaryl)-(C1-C6)-alkyl-, (C6-C10)-aryl-(C1-C6)-alkyl-, (5- to 10-membered heteroaryl)-O—(C1-C6)-alkyl-, or (C6-C10)-aryl-O—(C1-C6)-alkyl-, wherein each occurrence of R″ is independently substituted with 0-5 substituents selected from: halogen, —R o , —OR o , oxo, —CH 2 OR o ,—CH 2 N(R o ) 2 , —C(O)N(R o ) 2 , —C(O)OR o , —NO 2 , —NCS, —CN, —CF 3 , —OCF 3 and —N(R o ) 2 , wherein each occurrence of R o is independently selected from: —(C1-C6)-aliphatic, (C3-C6)-cycloalkyl, 3- to 6-membered heterocyclyl, 5- to 10-membered heteroaryl-, and (C6-C10)-aryl-.
3 . A compound of formula IV:
oxo, —CH 2 OR o ,
—CH 2 N(R o ) 2 , —C(O)N(R o ) 2 , —C(O)OR o , —NO 2 , —NCS, —CN, —CF 3 , —OCF 3 and —N(R o ) 2 , wherein each occurrence of R o is independently selected from:
—(C1-C6)-aliphatic, (C3-C6)-cycloalkyl, 3- to 6-membered heterocyclyl, 5- to 10-membered heteroaryl-, and (C6-C10)-aryl-.
4 . A compound selected from:
Compound
Structure
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
or a pharmaceutically acceptable salt, hydrate, solvate, polymorph, isomer, or combination thereof.
5 . A pharmaceutical composition comprising a compound according to any one of claims 1 - 4 , or a pharmaceutically acceptable salt, hydrate, solvate, polymorph, isomer, or combination thereof, in a therapeutically effective amount; and an acceptable carrier, adjuvant or vehicle.
6 . The pharmaceutical composition according to claim 5 , wherein said composition further comprises a second therapeutic agent.
7 . The pharmaceutical composition according to claim 6 , wherein the second therapeutic agent is selected from an antipsychotic, memantine and an acetylcholine esterase inhibitor (AChE-I).
8 . The pharmaceutical composition according to claim 6 , wherein the second therapeutic agent is an antipsychotic selected from aripiprazole, olanzapine and ziprasidone, and the pharmaceutically acceptable salts, hydrates, solvates, and polymorphs thereof.
9 . The pharmaceutical composition according to claim 6 , wherein the second therapeutic agent is memantine, a pharmaceutically acceptable salt, hydrate, solvate, or polymorph thereof
10 . The pharmaceutical composition according to claim 6 , wherein the second therapeutic agent is an AChE-I selected from Donepezil, Galantamine, and Rivastigmine, and the pharmaceutically acceptable salts, hydrates, solvates, and polymorphs thereof.
11 . A method of treating cognitive impairment associated with a central nervous system (CNS) disorder in a subject in need thereof, comprising the step of administering a compound according to any one of claims 1 - 4 or a pharmaceutical composition according to any one of claims 5 - 10 .
12 . The method of claim 11 , wherein the CNS disorder is age-related cognitive impairment.
13 . The method of claim 12 , wherein the age-related cognitive impairment is Mild Cognitive Impairment (MCI).
14 . The method of claim 13 , wherein the Mild Cognitive Impairment is amnestic Mild Cognitive Impairment (AMCI).
15 . The method according to claim 11 , wherein the CNS disorder is dementia.
16 . The method of claim 15 , wherein the dementia is Alzheimer's disease.
17 . The method of claim 11 , wherein the CNS disorder is schizophrenia or bipolar disorder.
18 . The method of claim 11 , wherein the CNS disorder is amyotrophic lateral sclerosis (ALS).
19 . The method of claim 11 , wherein the CNS disorder is post traumatic stress disorder (PTSD).
20 . The method of claim 11 , wherein the CNS disorder is associated with cancer therapy.
21 . The method of claim 11 , wherein the CNS disorder is mental retardation.
22 . The method of claim 11 , wherein the CNS disorder is Parkinson's disease (PD).
23 . The method of claim 11 , wherein the CNS disorder is autism.
24 . The method of claim 11 , wherein the CNS disorder is compulsive behavior.
25 . The method of claim 11 , wherein the CNS disorder is substance addiction.
26 . A method of treating a brain cancer in a subject in need thereof, comprising the step of administering a compound according to any one of claims 1 - 4 or a pharmaceutical composition according to any one of claims 5 - 10 .
27 . A method of treating cognitive impairment associated with a brain cancer in a subject in need thereof, comprising the step of administering a compound according to any one of claims 1 - 4 or a pharmaceutical composition according to any one of claims 5 - 10 .
28 . The method of claim 26 or 27 , wherein the compound is selected from:
Compound
Structure
1
2
3
4
5
6
7
8
9
12
44
45
46
47
48
49
50
51
52
53
54
55
56
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
or a pharmaceutically acceptable salt, hydrate, solvate, polymorph, isomer, or combination thereof.
29 . The method of claim 26 or 27 , wherein said brain cancer is medulloblastoma.
30 . The method of claim 28 , wherein said brain cancer is medulloblastoma.
31 . A compound of formula V:
—SO 2 R, —SO 2 N(R) 2 , —SO 3 R, —(CR 2 ) 1-3 R, —(CR 2 ) 1-3 —OR, —(CR 2 ) 1-3 —R, (CR 2 ) 1-3 —R, —(CR 2 ) 0-3 —C(O)NR(CR 2 ) 0-3 R, —(CR 2 ) 0-3 —C(O)NR(CR 2 ) 0-3 OR, —C(O)R, —(O)C(O)R, —C(O)CH 2 C(O)R, —C(S)R, —C(S)OR, —C(O)OR, —(O)C(O)OR, —(O)C(O)N(R) 2 , —OC(O)R, —C(O)N(R) 2 , —OC(O)N(R) 2 , —C(S)N(R) 2 , —(CR 2 ) 0-3 NHC(O)R, —N(R)N(R)COR, —N(R)N(R)C(O)OR, —N(R)N(R)CON(R) 2 , —N(R)SO 2 R, —N(R)SO 2 N(R) 2 , —N(R)C(O)OR, —N(R)C(O)R, —N(R)C(S)R, —N(R)C(O)N(R) 2 , —N(R)C(S)N(R) 2 , —N(COR)COR, —N(OR)R, —C(═NH)N(R) 2 , —C(O)N(OR)R, —C(═NOR)R, —OP(O)(OR) 2 , —P(O)(R) 2 , —P(O)(OR) 2 , —P(O)(H)(OR), C≡C—R 8 , CH 2 CF 3 , and CHF 3 ;
each occurrence of R 8 is —H, —(C1-C6) alkyl, —(C3-C6) cycloalkyl, —(C1-C6) alkyl-(C3-C6) cycloalkyl, —(C1-C6) alkyl-(C6-C10) aryl, —(C6-C10) aryl, -5-10 membered heteroaryl, or —(C1-C6) alkyl-5-10 membered heteroaryl;
wherein each R 8 excluding —H and —(C1-C6) alkyl is independently substituted by 0-5 of -halogen, —(C1-C6) alkyl, —CF 3 , —OCF 3 , or O—(C1-C6) alkyl;
R 3 is absent or is selected from:
halogen, —R, —OR, —NO 2 , —NCS, —CN, —CF 3 , —OCF 3 , —SiR 3 , —N(R) 2 , —SR, —SOR, —SO 2 R, —SO 2 N(R) 2 , —SO 3 R, —(CR 2 ) 1-3 R, —(CR 2 ) 1-3 —OR, —(CR 2 ) 0-3 —C(O)NR(CR 2 ) 0-3 R, —(CR 2 ) 0-3 —C(O)NR(CR 2 ) 0-3 OR, —C(O)R, —C(O)C(O)R, —C(O)CH 2 C(O)R, —C(S)R, —C(S)OR, —C(O)OR, —(O)C(O)OR, —(O)C(O)N(R) 2 , —OC(O)R, —C(O)N(R) 2 , —OC(O)N(R) 2 , —C(S)N(R) 2 , —(CR 2 ) 0-3 NHC(O)R, —N(R)N(R)COR, —N(R)N(R)C(O)OR, —N(R)N(R)CON(R) 2 , —N(R)SO 2 R, —N(R)SO 2 N(R) 2 , —N(R)C(O)OR, —N(R)C(O)R, —N(R)C(S)R, —N(R)C(O)N(R) 2 , —N(R)C(S)N(R) 2 , —N(COR)COR, —N(OR)R, —C(═NH)N(R) 2 , —C(O)N(OR)R, —C(═NOR)R, —OP(O)(OR) 2 , —P(O)(R) 2 , —P(O)(OR) 2 , —P(O)(H)(OR), C≡C—R 9 , COOMe, COOEt, —(C1-C6)alkyl-C≡C—R 10 , CH 2 —OR 10 , and CH 2 —O—CH 2 —R 10 ;
wherein each of R 9 is selected from —H, —(C1-C6) alkyl, —(C6-C10) aryl, -5-10 membered heteroaryl, —(C1 -C6) alkyl-(C6-C10) aryl, —(C1-C6) alkyl-5-10 membered heteroaryl, —(C3-C6) cycloalkyl, —(C1-C6) alkyl-(C3-C6) cycloalkyl, —C(O)—(C6-C10) aryl,
wherein each R 9 is independently substituted with 0-5 R 11 ;
wherein each occurrence of R 11 is independently selected from -halogen, —CF 3 , —OCF 3 , —Ome, —(C6-C10) aryl, —(C1-C6)alkyl, and -5 to 10 membered heteroaryl,
wherein R 10 is selected from —H, —(C1-C6) alkyl, —(C6-C10) aryl, -5-10 membered heteroaryl, —(C3-C6) cycloalkyl, —CH 2 —(C3-C6) cycloalkyl, —CH 2 -(C6-C10) aryl, and —CH 2 -5-10-membered heteroaryl,
wherein each R 10 is independently substituted with 0-5 R′;
wherein R 7 is selected from —(C1-C6)alkyl, —(C3-C6)cycloalkyl, -5 to 10 membered heteroaryl, —(C6-C10) aryl, —(C6-C10)aryl-(C1-C6)alkyl, and -5 to 10 membered heteroaryl-(C1-C6)alkyl, and -5-10 membered heteroaryl,
wherein each R7 is independently substituted with 0-5 R′;
each R 6 is independently —H or —(C1-C6)alkyl;
each R 7 is independently —H or —(C1-C6)alkyl;
each R 8 is independently —(C1-C6)alkyl, —(C3-C10)-cycloalkyl, (C6-C10)-aryl, or 5- to 10-membered heteroaryl, wherein each occurrence of R 8 is independently substituted with 0-5 R′;
each R 10 is independently —(C3-C10)-cycloalkyl, 3- to 10-membered heterocyclyl-, (C6-C10)-aryl, or 5- to 10-membered heteroaryl, wherein each occurrence of R 10 is independently substituted with 0-5 R′;
each R is independently selected from:
H—,
(C1-C12)-aliphatic-,
(C3-C10)-cycloalkyl-,
(C3-C10)-cycloalkenyl-,
[(C3-C10)-cycloalkyl]-(C1-C12)-aliphatic-,
[(C3-C10)-cycloalkenyl]-(C1-C12)-aliphatic-,
[(C3-C10)-cycloalkyl]-O—(C1-C12)-aliphatic-,
[(C3-C10)-cycloalkenyl]-O—(C1-C12)-aliphatic-,
(C6-C10)-aryl-,
(C6-C10)-aryl-(C1-C12)aliphatic-,
(C6-C10)-aryl-O—(C1-C12)aliphatic-,
(C6-C10)-aryl-N(R″)—(C1-C12)aliphatic-,
3- to 10-membered heterocyclyl-,
(3- to 10-membered heterocyclyl)-(C1-C12)aliphatic-,
(3- to 10-membered heterocyclyl)-O—(C1-C12)aliphatic-,
(3- to 10-membered heterocyclyl)-N(R″)—(C1-C12)aliphatic-,
5- to 10-membered heteroaryl-,
(5- to 10-membered heteroaryl)-(C1-C12)-aliphatic-,
(5- to 10-membered heteroaryl)-O—(C1-C12)-aliphatic-; and
(5- to 10-membered heteroaryl)-N(R″)—(C1-C12)-aliphatic-;
wherein said heterocyclyl has 1-4 heteroatoms independently selected from N, NH, O, S, SO, and SO 2 , and said heteroaryl has 1-4 heteroatoms independently selected from N, NH, O, and S;
wherein each occurrence of R is independently substituted with 0-5 R′;
or when two R groups bound to the same atom, the two R groups may be taken together with the atom to which they are bound to form a 3- to 10-membered aromatic or non-aromatic ring having 0-4 heteroatoms independently selected from N, NH, O, S, SO, and SO 2 , wherein said ring is optionally substituted with 0-5 R′, and wherein said ring is optionally fused to a (C6-C10)aryl, 5- to 10-membered heteroaryl, (C3-C10)cycloalkyl, or a 3- to 10-membered heterocyclyl;
wherein each occurrence of R′ is independently selected from halogen, —R″, —OR″, oxo, —CH 2 OR″, —CH 2 NR″ 2 , —C(O)N(R″) 2 , —C(O)OR″, —NO 2 , —NCS, —CN, —CF 3 , —OCF 3 and —N(R″) 2 ;
wherein each occurrence of R″ is independently selected from H, —(C1-C6)-alkyl, —(C1-C6)-aliphatic, (C3-C6)-cycloalkyl, 3- to 6-membered heterocyclyl, 5- to 10-membered heteroaryl-, (C6-C10)-aryl-, (5- to 10-membered heteroaryl)-(C1-C6)-alkyl-, (C6-C10)-aryl-(C1-C6)-alkyl-, (5- to 10-membered heteroaryl)-O—(C1-C6)-alkyl-, and (C6-C10)-aryl-O—(C1-C6)-alkyl-, wherein each occurrence of R″ is independently substituted with 0-3 substituents selected from: halogen, —R o , —OR o , oxo, —CH 2 OR o ,—CH 2 N(R o ) 2 , —C(O)N(R o ) 2 , —C(O)OR o , —NO 2 , —NCS, —CN, —CF 3 , —OCF 3 and —N(R o ) 2 , wherein each occurrence of R o is independently selected from: —(C1-C6)-aliphatic, (C3-C6)-cycloalkyl, 3- to 6-membered heterocyclyl, 5- to 10-membered heteroaryl-, and (C6-C10)-aryl-.
32 . A compound of formula VI:
-halogen, —(C1-C6) alkyl, —CF 3 , —OCF 3 , or —O—(C1-C6) alkyl,
wherein R 9 is selected from —H, —(C1-C6) alkyl, —(C6-C10) aryl, -5-10 membered heteroaryl, —(C1 -C6) alkyl-(C6-C10) aryl, —(C1-C6) alkyl-5-10 membered heteroaryl, —(C3-C6) cycloalkyl, and —(C1-C6) alkyl-(C3-C6) cycloalkyl;
wherein each R 9 is independently substituted with 0-5 R 11 ;
wherein each occurrence of RH is independently selected from -halogen, —CF 3 , —OCF 3 , —OMe, —(C6-C10) aryl, —(C1-C6)alkyl, and -5 to 10 membered heteroaryl,
R 3 is selected from: -halogen, —CN, —C≡CR
wherein R 3 is substituted with 0-5 R′;
each occurrence of R 4 and R 5 is independently —H, —(C1-C6)alkyl, or —(C1-C6) alkyl-(C6-C10) aryl; the (C6-C10) aryl being independently substituted with 0-5 -halogen;
each R 6 is independently —H or —(C1-C6)alkyl;
wherein each occurrence of R′ is independently selected from halogen, —R″, —OR″, oxo, —CH 2 OR″, —CH 2 NR″ 2 , —C(O)N(R″) 2 , —C(O)OR″, —NO 2 , —NCS, —CN, —CF 3 , —OCF 3 and —N(R″) 2 ;
wherein each occurrence of R″ is independently selected from H, —(C1-C6)-alkyl, —(C1-C6)-aliphatic, (C3-C6)-cycloalkyl, 3- to 6-membered heterocyclyl, 5- to 10-membered heteroaryl-, (C6-C10)-aryl-, (5- to 10-membered heteroaryl)-(C1-C6)-alkyl-, (C6-C10)-aryl-(C1-C6)-alkyl-, (5- to 10-membered heteroaryl)-O—(C1-C6)-alkyl-, or (C6-C10)-aryl-O—(C1-C6)-alkyl-, wherein each occurrence of R″ is independently substituted with 0-5 substituents selected from: halogen, —R o , —OR o , oxo, —CH 2 OR o ,)—CH 2 N(R o ) 2 , —C(O)N(R o ) 2 , —C(O)OR o , —NO 2 , —NCS, —CN, —CF 3 , —OCF 3 and —N(R o ) 2 , wherein each occurrence of R o is independently selected from: —(C1-C6)-aliphatic, (C3-C6)-cycloalkyl, 3- to 6-membered heterocyclyl, 5- to 10-membered heteroaryl-, and (C6-C10)-aryl.
33 . A compound of formula VII:
or a pharmaceutically acceptable salt, hydrate, solvate, polymorph, isomer, or combination thereof, wherein:
m is 0-3;
each R 1 is independently selected from: -halogen, —OMe, —C≡C—R 9 , —CN, —CHF 2 , —CH 2 CF 3 , —CF 3 , —OCF 3 , —(C1-C6) alkyl, —(C6-C10) aryl, —(C1-C6) alkyl-(C6-C10) aryl, -5-10 membered heteroaryl, —(C1-C6) alkyl-5-10 membered heteroaryl, and —(C3-C6) cycloalkyl;
wherein R 9 is —H, —(C1-C6) alkyl, —(C3-C6) cycloalkyl, —(C1-C6) alkyl-(C3-C6) cycloalkyl, —(C1-C6) alkyl-(C6-C10) aryl, —(C6-C10) aryl, -5-10 membered heteroaryl, or —(C1-C6) alkyl-5-10 membered heteroaryl;
wherein each R 9 excluding —H and —(C1-C6) alkyl is independently substituted by 0-5 of -halogen, —(C1-C6) alkyl, —CF 3 , —OCF 3 , or 0—(C1-C6) alkyl;
R 2 is —(CH 2 ) n OR 8 , or —(CH 2 ) n O(CH 2 ) n R 8 , wherein each occurrence of R 8 is independently —H, —(C1-C6)alkyl, —(C6-C10)-aryl, 5- to 10-membered heteroaryl-, 5-10 membered heteroaryl-(C1-C6) alkyl-, —(C3-C6)cycloalkyl, —(C1-C6) alkyl-(C6-C10) aryl, or —(C1-C6) alkyl-(C3-C6) cycloalkyl;
wherein each R 8 excluding —H and —(C1-C6) alkyl is independently substituted by 0-5 of -halogen, —(C1-C6) alkyl, —CF 3 , —OCF 3 , or —O—(C1-C6) alkyl;
wherein n is an integer from 0-4;
wherein R 2 is independently substituted with 0-5 R′;
R 3 is selected from: -halogen, —CN, —C≡CR 9 , COOMe, —COOEt, —(C1-C6)alkyl-C≡C—-R 10 , —CH 2 —O—R 10 , —CH 2 —O—CH 2 —R 10
wherein R 9 is selected from —H, —(C1-C6) alkyl, —(C6-C10) aryl, -5-10 membered heteroaryl, —(C1 -C6) alkyl-(C6-C10) aryl, —(C1-C6) alkyl-5-10 membered heteroaryl, —(C3-C6) cycloalkyl, —(C1-C6) alkyl-(C3-C6) cycloalkyl, and —C(O)—(C6-C10) aryl;
wherein each R 9 is independently substituted with 0-5 R 11 ;
wherein R 10 is selected from —H, —(C1-C6) alkyl, —(C6-C10) aryl, -5-10 membered heteroaryl, —(C3-C6) cycloalkyl, —CH 2 —(C3-C6) cycloalkyl, —CH 2 -(C6-C10) aryl, and —CH 2 -5-10-membered heteroaryl,
wherein each R 10 is independently substituted with 0-5 R′;
wherein each occurrence of R″ is independently selected from -halogen, —CF 3 , —OCF 3 , —Ome, —(C6-C10) aryl, —(C1-C6)alkyl, and -5 to 10 membered heteroaryl,
wherein R 7 is selected from —(C1-C6)alkyl, —(C3-C6)cycloalkyl, -5 to 10 membered heteroaryl, —(C6-C10) aryl, —(C6-C10)aryl-(C1-C6)alkyl, and -5 to 10 membered heteroaryl-(C1-C6)alkyl, and -5-10 membered heteroaryl;
wherein each R 7 is independently substituted with 0-5 R′;
wherein R 3 is substituted with 0-5 R′;
each occurrence of R 4 and R 5 is independently —H or —(C1-C6)alkyl;
each R 6 is independently —H or —(C1-C6)alkyl;
wherein each occurrence of R′ is independently selected from halogen, —R″, —OR″, oxo, —CH 2 OR″, —CH 2 NR″ 2 , —C(O)N(R″) 2 , —C(O)OR″, —NO 2 , —NCS, —CN, —CF 3 , —OCF 3 and —N(R″) 2 , —OMe;
wherein each occurrence of R″ is independently selected from H, —(C1-C6)-alkyl, —(C1-C6)-aliphatic, (C3-C6)-cycloalkyl, 3- to 6-membered heterocyclyl, 5- to 10-membered heteroaryl-, (C6-C10)-aryl-, (5- to 10-membered heteroaryl)-(C1-C6)-alkyl-, (C6-C10)-aryl-(C1-C6)-alkyl-, (5- to 10-membered heteroaryl)-O—(C1-C6)-alkyl-, and (C6-C10)-aryl-O—(C1-C6)-alkyl-, wherein each occurrence of R″ is independently substituted with 0-5 R t independently selected from: halogen, —R o , —OR o , oxo, —CH 2 OR o ,
—CH 2 N(R o ) 2 , —C(O)N(R o ) 2 , —C(O)OR o , —NO 2 , —NCS, —CN, —CF 3 , —OCF 3 and —N(R o ) 2 , wherein each occurrence of R o is independently selected from:
—(C1-C6)-aliphatic, (C3-C6)-cycloalkyl, 3- to 6-membered heterocyclyl, 5- to 10-membered heteroaryl-, and (C6-C10)-aryl-.
34 . A compound of formula VIII:
wherein R 9 is selected from —H, —(C1-C6) alkyl, —(C6-C10) aryl, -5-10 membered heteroaryl, —(C1-C6) alkyl-(C6-C10) aryl, —(C1-C6) alkyl-5-10 membered heteroaryl, —(C3-C6) cycloalkyl, —(C1-C6) alkyl-(C3-C6) cycloalkyl, and —C(O)-(C6-C10) aryl;
wherein each R 9 is independently substituted with 0-5 R 11 ;
wherein each occurrence of R 11 is independently selected from -halogen, —CF 3 , —OCF 3 , —Ome, —(C6-C10) aryl, —(C1-C6)alkyl, and -5 to 10 membered heteroaryl,
wherein R 10 is selected from —H, —(C1-C6) alkyl, —(C6-C10) aryl, -5-10 membered heteroaryl, —(C3-C6) cycloalkyl, —CH 2 —(C3-C6) cycloalkyl, —CH 2 -(C6-C10) aryl, and —CH 2 -5-10-membered heteroaryl,
wherein each R 10 is independently substituted with 0-5 R′;
wherein R 7 is selected from —(C1-C6)alkyl, —(C3-C6)cycloalkyl, -5 to 10 membered heteroaryl, —(C6-C10) aryl, —(C6-C10)aryl-(C1-C6)alkyl, and -5 to 10 membered heteroaryl-(C1-C6)alkyl, and -5-10 membered heteroaryl; wherein each R 7 is independently substituted with 0-5 R′;
each occurrence of R 4 and R 5 is independently —H, —(C1-C6)alkyl, or —(C1-C6) alkyl-(C6-C10) aryl; the (C6-C10) aryl being independently substituted with 0-5 -halogen;
each R 6 is independently —H or —(C1-C6)alkyl.
35 . A compound of formula IX:
or a pharmaceutically acceptable salt, hydrate, solvate, polymorph, isomer, or combination thereof, wherein:
each R 1 is independently selected from: —Cl, —OMe, —CF 3 , and —OCF 3 ;
wherein R 9 is —H, —(C1-C6) alkyl, —(C3-C6) cycloalkyl, —(C1-C6) alkyl-(C3-C6) cycloalkyl, —(C1-C6) alkyl-(C6-C10) aryl, —(C6-C10) aryl, -5-10 membered heteroaryl, or —(C1-C6) alkyl-5-10 membered heteroaryl;
wherein each R 9 excluding —H and —(C1-C6) alkyl is independently substituted by 0-5 of -halogen, —(C1-C6) alkyl, —CF 3 , —OCF 3 , or 0—(C1-C6) alkyl;
R 2 is —H, CH 2 OR 8 , CH 3 , CH 2 -phenyl, wherein each occurrence of R 8 is independently —H, —(C1-C6)alkyl, —(C6-C10)-aryl, 5- to 10-membered heteroaryl-, 5-10 membered heteroaryl-(C1-C6) alkyl-, —(C3-C6)cycloalkyl, —(C1-C6) alkyl-(C6-C10) aryl, or —(C1-C6) alkyl-(C3-C6) cycloalkyl;
wherein each R 8 excluding —H and —(C1-C6) alkyl is independently substituted by 0-5 of -halogen, —(C1-C6) alkyl, —CF 3 , —OCF 3 , or —O—(C1-C6) alkyl;
R 3 is selected from: —C≡CR 9 , —(C1-C6)alkyl-C≡C—R 10 ,
wherein R 9 is selected from —H, —(C1-C6) alkyl, —(C6-C10) aryl, -5-10 membered heteroaryl, —(C1 -C6) alkyl-(C6-C10) aryl, —(C1-C6) alkyl-5-10 membered heteroaryl, —(C3-C6) cycloalkyl, —(C1-C6) alkyl-(C3-C6) cycloalkyl, and —C(O)—(C6-C10) aryl;
wherein each R 9 is independently substituted with 0-5 R 11 ;
wherein R 10 is selected from —H, —(C1-C6) alkyl, —(C6-C10) aryl, -5-10 membered heteroaryl, —(C3-C6) cycloalkyl, —CH 2—(C3-C6) cycloalkyl, —CH 2 -(C6-C10) aryl, and —CH 2 -5-10-membered heteroaryl,
wherein each Rim is independently substituted with 0-5 R′;
wherein each occurrence of R 11 is independently selected from -halogen, —CF 3 , —OCF 3 , —Ome, —(C6-C10) aryl, —(C1-C6)alkyl, and -5 to 10 membered heteroaryl,
wherein R 7 is selected from —(C1-C6)alkyl, —(C3-C6)cycloalkyl, -5 to 10 membered heteroaryl, —(C6-C10) aryl, —(C6-C10)aryl-(C1-C6)alkyl, and -5 to 10 membered heteroaryl-(C1-C6)alkyl, and -5-10 membered heteroaryl;
wherein each R 7 is independently substituted with 0-5 R′;
wherein R 3 is substituted with 0-5 R′;
each occurrence of R 4 and R 5 is independently —H or —(C1-C6)allcyl;
each R 6 is independently —H or —(C1-C6)alkyl.
36 . A compound selected from:
or a pharmaceutically acceptable salt, hydrate, solvate, polymorph, isomer, or combination thereof.
37 . A pharmaceutical composition comprising a compound according to any one of claims 31 - 36 , or a pharmaceutically acceptable salt, hydrate, solvate, polymorph, isomer, or combination thereof, in a therapeutically effective amount; and an acceptable carrier, adjuvant or vehicle.
38 . The pharmaceutical composition according to claim 37 , wherein said composition further comprises a second therapeutic agent.
39 . The pharmaceutical composition according to claim 38 , wherein the second therapeutic agent is selected from an antipsychotic, memantine and an acetylcholine esterase inhibitor (AChE-I).
40 . The pharmaceutical composition according to claim 38 , wherein the second therapeutic agent is an antipsychotic selected from aripiprazole, olanzapine and ziprasidone, and the pharmaceutically acceptable salts, hydrates, solvates, and polymorphs thereof.
41 . The pharmaceutical composition according to claim 38 , wherein the second therapeutic agent is memantine, a pharmaceutically acceptable salt, hydrate, solvate, or polymorph thereof.
42 . The pharmaceutical composition according to claim 38 , wherein the second therapeutic agent is an AChE-I selected from Donepezil, Galantamine, and Rivastigmine, and the pharmaceutically acceptable salts, hydrates, solvates, and polymorphs thereof.
43 . A method of treating cognitive impairment associated with a central nervous system (CNS) disorder in a subject in need thereof, comprising the step of administering a compound according to any one of claims 31 - 36 or a pharmaceutical composition according to any one of claims 37 - 42 .
44 . The method of claim 43 , wherein the CNS disorder is age-related cognitive impairment.
45 . The method of claim 44 , wherein the age-related cognitive impairment is Mild Cognitive Impairment (MCI).
46 . The method of claim 45 , wherein the Mild Cognitive Impairment is amnestic Mild Cognitive Impairment (AMCI).
47 . The method according to claim 43 , wherein the CNS disorder is dementia.
48 . The method of claim 47 , wherein the dementia is Alzheimer's disease.
49 . The method of claim 43 , wherein the CNS disorder is schizophrenia or bipolar disorder.
50 . The method of claim 43 , wherein the CNS disorder is amyotrophic lateral sclerosis (ALS).
51 . The method of claim 43 , wherein the CNS disorder is post traumatic stress disorder (PTSD).
52 . The method of claim 43 , wherein the CNS disorder is associated with cancer therapy.
53 . The method of claim 43 , wherein the CNS disorder is mental retardation.
54 . The method of claim 43 , wherein the CNS disorder is Parkinson's disease (PD).
55 . The method of claim 43 , wherein the CNS disorder is autism.
56 . The method of claim 43 , wherein the CNS disorder is compulsive behavior.
57 . The method of claim 43 , wherein the CNS disorder is substance addiction.
58 . A method of treating a brain cancer in a subject in need thereof, comprising the step of administering a compound according to any one of claims 31 - 36 , or a pharmaceutical composition according to any one of claims 37 - 42 .
59 . A method of treating cognitive impairment associated with a brain cancer in a subject in need thereof, comprising the step of administering a compound according to any one of claims 31 - 36 , or a pharmaceutical composition according to any one of claims 34 - 39 .
60 . The method of claim 58 or 59 , wherein the compound is selected from:
or a pharmaceutically acceptable salt, hydrate, solvate, polymorph, isomer, or combination thereof.
61 . The method of claim 58 or 59 , wherein said brain cancer is medulloblastoma.
62 . The method of claim 60 , wherein said brain cancer is medulloblastoma.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.